Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Amarin

Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Eicosapentanoic acid ethyl ester; EPA-Vascepa; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl; Icosapentaenoic acid ethyl ester; LAX-101; LAX-101c; Miraxion™; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Ultra-pure ethyl ecosapentaenoic acid; Ultra-pure ethyl EPA; Vascepa

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scarista
  • Developer Amarin Corporation; Biologix FZCo; Eddingpharm; University of Leeds; Yorkshire Cancer Research
  • Class Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Phase III Colorectal cancer; Liver metastases
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 04 Jan 2019 Amarin anticipates to submit an sNDA to seek an expanded indication for ethyl eicosapentaenoic acid in USA before the end of Q1 2019
  • 15 Nov 2018 Amarin intends to submit NDA to Health Canada for Hypertriglyceridaemia in early 2019
  • 15 Nov 2018 Efficacy data from the phase III REDUCE-IT trial in Hypertriglyceridaemia (Cardiovascular diseases) released by Amarin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top